Gewinn & Umsatz News zur GSK Aktie

 

On this episode of Stock Movers with Alexis Christoforous: - Nuvalent (NUVL) shares are higher on news GSK agreed to buy Nuvalent for $10.6 billion, securing a US biotech firm developing treatments for lung cancer. - JM Smucker (SJM) shares are on the move after it posted fourth-quarter profits that beat Wall Street expectations as higher prices helped boost the packaged food company. - Vail Resorts (MTN) is dropping after the ski resort operator cut its net income guidance for the full year, attributing the reduction to “historically challenging” weather conditions in the western US. The guidance missed the average analyst estimate. (Source: Bloomberg)...

Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...

Versicherer Talanx verdient mehr als erwartet +++ Iran-Krieg treibt Gewinn von TotalEnergies an +++ Starke Medikamentennachfrage stützt AstraZeneca und GSK an +++ Der Newsblog....

Iran-Krieg treibt Gewinn von TotalEnergies an +++ Starke Medikamentennachfrage stützt AstraZeneca und GSK an +++ Wacker Chemie verbessert operatives Ergebnis +++ Der Newsblog....

AstraZeneca and GSK, the U.K.'s second and ninth most valuable companies, both saw first-quarter profits beat expectations early Wednesday....

Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...

BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - GSK (GSK, GSK.L, GS71.DE) reported first quarter pretax profit of 2.14 billion pounds compared to 2.11 billion pounds, prior year. Earnings per share was 42.6 ......

The pharmaceutical giant said core operating profit for the first quarter was £2.65 billion compared with £2.53 billion for the same period a year earlier....

GSK Plc's profit was higher than analysts expected in the first quarter, helped by the drugmaker's specialty medicines for HIV, cancer and immune diseases....

LONDON (dpa-AFX) - GSK plc (GSK, GSK.L) announced encouraging findings from its global phase I BEHOLD-1 clinical trial for mocertatug rezetecan (Mo-Rez), a novel antibody-drug conjugate (ADC) targ......

Mo-Rez reduced or eliminated tumours in over 60% of patients and is expected to be a blockbuster drugGSK has revealed positive results for a treatment for gynaecological cancers as its chief executive, Luke Miels, steps up drug development efforts at the group.The company said that in an early-stage trial Mocertatug Rezetecan, known as Mo-Rez, shrank or eliminated tumours in 62% of patients with ovarian cancer where chemotherapy had failed, and in 67% of those with endometrial cancer. Continue reading......

GSK beat profit expectations in the fourth quarter, driven by demand for its HIV drugs and Asthma medicine....

LONDON (dpa-AFX) - Der Pharmakonzern GSK hat dank eines unerwartet starken Schlussspurts im abgelaufenen Jahr besser abgeschnitten als gedacht. "GSK hat 2025 erneut eine starke Leistung erzielt, die vor allem auf den Bereich ......

LONDON (dpa-AFX) - British drug major GSK plc (GSK, GSK.L) reported Wednesday higher profit and revenues in its fourth quarter, and issued fiscal 2026 outlook, expecting increase in core profit an......

Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...

LONDON (dpa-AFX) - GSK plc (GSK) revealed earnings for its fourth quarter that Increased, from last yearThe company's bottom line came in at GBP727 million, or GBP0.156 per share. This compares wi......

GSK Plc reported better-than-expected profit in the fourth quarter, buoyed by its HIV and asthma medicines....

Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...

Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...

LONDON (dpa-AFX) - GSK plc (GSK, GSK.L) reported positive outcomes from its two pivotal phase III trials, B-Well 1 and B-Well 2, which evaluated bepirovirsen, an investigational antisense oligonuc......